Aytu Biopharma, Inc.

AYTU

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001385818

E

weakest fifth of 370 graded peers in healthcare

rank 335 of 370; percentile 90.5; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	C percentile 49.4
Solvency	E percentile 86.9
Growth and financing	D percentile 68.7
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $105.0M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Sep 22, 2026 46 days before the rescan; latest periodic filing 10-K received Sep 22, 2026
Last close	$1.81 2026-11-05; market equity $19.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Sep 22, 2026

Aytu BioPharma, Inc. ("Aytu," the "Company," "we," "us," or "our") is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the "Nasdaq") under the ticker symbol "AYTU.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 49.4						
Gross profitability	35.1%	32.3%		39.3	365	2026-06-30
Return on invested capital	not computable	9.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(15.3%)	(6.6%)	28.8	802	2026-06-30
Gross margin stability, five years	7.1 pts	2.8 pts	80.1	242	2026-06-30
Solvency, sleeve percentile 86.9					
Twelve-month failure probability	not computable	0.08%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	not computable	(0.37)			
latest aligned inputs end 2023-06-30; latest annual assets end 2026-06-30					
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2020-06-30; latest annual assets end 2026-06-30					
Current ratio	1.13x	2.94x	86.9	828	2026-06-30
Growth and financing, sleeve percentile 68.7					
Revenue growth, three-year compound	(18.8%)	10.0%	88.8	412	2026-06-30
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 8					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(8.4%)	2.2%	66.8	696	2026-06-30
Net share issuance, one year	9.6%	2.5%	50.6	630	2026-09-15

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 17,207,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
330	Aclaris Therapeutics, Inc. (ACRS)	89.2	E	short runway, fortress balance sheet
331	Brookdale Senior Living Inc. (BKD)	89.4	E	
332	Canopy Growth Corp. (CGC)	89.7	E	dilution, fortress balance sheet
333	Lifeward Ltd. (LFWD)	90.0	E	dilution, late filer
334	Editas Medicine, Inc. (EDIT)	90.2	E	fortress balance sheet
335	Aytu Biopharma, Inc. (AYTU)	90.5	E	fortress balance sheet
336	Q32 Bio Inc. (QTTB)	90.8	E	
337	Dyadic International Inc. (DYAI)	91.1	E	short runway, distress
338	Precision Biosciences Inc. (DTIL)	91.3	E	dilution, fortress balance sheet
339	Beyond Air, Inc. (XAIR)	91.6	E	dilution, short runway, distress
340	Century Therapeutics, Inc. (IPSC)	91.9	E	dilution, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(5.7%)	(2.1%)	46
Distance from 52-week high	(36.9%)	(30.5%)	43
EBIT to enterprise value	(310.4%)	(1.5%)	2
Free cash flow yield	16.4%	(1.0%)	95
Book value to price	1.77	0.29	94
Sales to price	2.89	0.30	93
Composite equity issuance, five years	206.5%	21.4%	89
Relative strength against the sector, log excess return	(0.23)	(0.19)	46

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2026-06-30	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$26.3M
Operating cash flow, four quarters	$3.3M
Months of runway	not finite
Days since last periodic filing	46 (10-K received Sep 22, 2026)
Median daily dollar volume, 63 sessions	$49,010

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$36.8M	2026-06-30	2026-09-22	10-K	26-030908
2	assets	us-gaap:Assets	$105.0M	2026-06-30	2026-09-22	10-K	26-030908
3	operating income	us-gaap:OperatingIncomeLoss	-$8.3M	2026-06-30	2026-09-22	10-K	26-030908
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$14.2M	2026-06-30	2026-09-22	10-K	26-030908
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$21,000	2026-06-30	2026-09-22	10-K	26-030908
6	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$9.1M	2026-06-30	2026-09-22	10-K	26-030908
7	book equity	us-gaap:StockholdersEquity	$35.3M	2026-06-30	2026-09-22	10-K	26-030908
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$26.3M	2026-06-30	2026-09-22	10-K	26-030908
9	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$10.9M	2025-06-30	2026-09-22	10-K	26-030908
10	book equity	us-gaap:StockholdersEquity	$19.0M	2025-06-30	2026-09-22	10-K	26-030908
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$31.0M	2025-06-30	2026-09-22	10-K	26-030908
12	net income	us-gaap:NetIncomeLoss	-$14.3M	2026-06-30	2026-09-22	10-K	26-030908
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.3M	2026-06-30	2026-09-22	10-K	26-030908
14	assets	us-gaap:Assets	$124.2M	2025-06-30	2026-09-22	10-K	26-030908
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$57.6M	2026-06-30	2026-09-22	10-K	26-030908
16	gross profit	us-gaap:GrossProfit	$45.8M	2025-06-30	2026-09-22	10-K	26-030908
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$66.4M	2025-06-30	2026-09-22	10-K	26-030908
18	gross profit	us-gaap:GrossProfit	$49.1M	2024-06-30	2025-09-23	10-K	25-029723

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$65.2M	2024-06-30	2025-09-23	10-K	25-029723
20	gross profit	us-gaap:GrossProfit	$66.6M	2023-06-30	2024-09-26	10-K	24-030062
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$107.4M	2023-06-30	2024-09-26	10-K	24-030062
22	gross profit	us-gaap:GrossProfit	$52.3M	2022-06-30	2023-10-12	10-K	23-016393
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$96.7M	2022-06-30	2023-10-12	10-K	23-016393
24	current assets	us-gaap:AssetsCurrent	$72.8M	2023-06-30	2023-10-12	10-K	23-016393
25	current liabilities	us-gaap:LiabilitiesCurrent	$69.0M	2023-06-30	2024-09-26	10-K	24-030062
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$304.1M	2023-06-30	2024-09-26	10-K	24-030062
27	operating income	us-gaap:OperatingIncomeLoss	-$17.1M	2023-06-30	2024-09-26	10-K	24-030062
28	book equity	us-gaap:StockholdersEquity	$39.4M	2023-06-30	2025-09-23	10-K	25-029723
29	assets	us-gaap:Assets	$136.5M	2023-06-30	2024-09-26	10-K	24-030062
30	liabilities	us-gaap:Liabilities	$97.1M	2023-06-30	2023-10-12	10-K	23-016393
31	depreciation amortization	us-gaap:Depreciation	$100,000	2026-06-30	2026-09-22	10-K	26-030908
32	operating income	us-gaap:OperatingIncomeLoss	-$21.1M	2020-06-30	2021-09-28	10-K	21-012825
33	interest expense	us-gaap:InterestExpense	$2.6M	2020-06-30	2020-10-06	10-K	20-010891
34	current assets	us-gaap:AssetsCurrent	$61.8M	2026-06-30	2026-09-22	10-K	26-030908
35	current liabilities	us-gaap:LiabilitiesCurrent	$54.7M	2026-06-30	2026-09-22	10-K	26-030908
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$29,000	2026-06-30	2026-09-22	10-K	26-030908
37	current assets	us-gaap:AssetsCurrent	$79.2M	2025-06-30	2026-09-22	10-K	26-030908
38	current liabilities	us-gaap:LiabilitiesCurrent	$63.1M	2025-06-30	2026-09-22	10-K	26-030908
39	assets	us-gaap:Assets	$118.1M	2024-06-30	2025-09-23	10-K	25-029723
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,866,708	2026-09-15	2026-09-22	10-K	26-030908
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,911,913	2025-09-15	2025-09-23	10-K	25-029723

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.